BioMedica Diagnostics released QuikCoag, which is developed for monitoring the growing prevalence of heart disease.
"The revenue base from our existing markets is being applied to leverage the introduction of affordable medical solutions in emerging economies," said Dr. Kirumira.
BioMedica is distinguished by its latest diagnostic technologies, which are provided at a cost appropriate to smaller health budgets.
Furthermore, the demand for BioMedica products has increased and the company is undertaking a $500,000 expansion project to increase production capacity.
"BioMedica has taken its technology from the lab to new markets around the world," said Stephen Lund, president and CEO of NSBI Nova Scotia Business Inc.